Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases

The Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases program is a federal funding opportunity administered by the National Institutes of Health within the U.S. Department of Health and Human Services, specifically through the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This program is designed to advance clinical research aligned with the institute’s mission to improve health outcomes related to rheumatic, musculoskeletal, and dermatologic conditions. The funding opportunity is currently in a forecasted stage, signaling NIH’s intent to formally release a Notice of Funding Opportunity and begin accepting applications at a later date. The primary purpose of this grant program is to support exploratory clinical trials that can contribute to meaningful advancements in the prevention, diagnosis, and treatment of arthritis, musculoskeletal disorders, and skin diseases. The program emphasizes translational research that bridges early scientific discoveries and clinical application. Projects funded under this program are expected to generate critical preliminary data that can inform larger, more definitive clinical trials in the future. The overarching goal is to accelerate the development of interventions that improve patient outcomes and functional health. Funding is intended to support short-term, interventional clinical studies that meet the National Institutes of Health definition of a clinical trial. Eligible projects may include early-stage investigations such as first-in-human studies, dose-finding or escalation trials, and safety or tolerability assessments. The program also supports Phase I and Phase II trials involving drugs, biologics, medical devices, behavioral interventions, and physical therapy approaches. Additionally, the funding may be used for studies designed to validate biomarkers or to support research in rare diseases where participant populations are limited. All proposed studies must be feasible within the defined budget and project period constraints. The program does not require cost sharing or matching funds, which lowers the financial barrier to entry for applicants. Award amounts are expected to range between three hundred thousand and six hundred thousand dollars per project. The estimated number of awards is four, indicating a competitive selection process. While total program funding is not specified, applicants should plan proposals carefully to align with the funding limits and NIH expectations for feasibility and impact. Eligibility for this funding opportunity is broad and inclusive, encompassing a wide range of entity types. Eligible applicants include public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations including small businesses, and various levels of government such as state, county, city, and tribal entities. Additional eligible applicants include federally recognized and non-recognized tribal organizations, public housing authorities, independent school districts, and even non-domestic institutions. Federal agencies, faith-based organizations, and regional entities are also eligible, reflecting NIH’s commitment to inclusive participation across sectors and geographies. The application process will be formally defined upon release of the full funding announcement, but applicants can expect to follow standard NIH submission procedures, likely through Grants.gov. At present, there are no specified pre-application requirements such as letters of intent. The estimated application due date is March 4, 2027, with awards expected to be made on the same date, followed by a project start date aligned with the award. As this is a forecasted opportunity, applicants are encouraged to begin early planning and monitor updates from NIH to ensure timely and complete submission once the opportunity is officially posted. Programmatic evaluation will likely focus on scientific merit, feasibility, innovation, and alignment with NIAMS priorities. While specific review criteria are not yet detailed, NIH typically employs peer review panels to assess applications based on rigor, significance, and potential impact. Applicants are advised to ensure that their proposals clearly articulate study design, expected outcomes, and relevance to improving patient care. For additional information or inquiries, interested parties may contact the program via the provided NIH email address.